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Objectives: This multicenter retrospective study of the initial U.S. experience evalu-
ated the safety and efficacy of temporary cardiac pacing with the Tempo® Tempo-
rary Pacing Lead.
Background: Despite increasing use of temporary cardiac pacing with the rapid
growth of structural heart procedures, temporary pacing leads have not significantly
improved. The Tempo lead is a new temporary pacing lead with a soft tip intended to
minimize the risk of perforation and a novel active fixation mechanism designed to
enhance lead stability.
Methods: Data from 269 consecutive structural heart procedures were collected.
Outcomes included device safety (absence of clinically significant cardiac perforation,
new pericardial effusion, or sustained ventricular arrhythmia) and efficacy (clinically
acceptable pacing thresholds with successful pace capture throughout the index pro-
cedure). Postprocedure practices and sustained lead performance were also
analyzed.
Results: The Tempo lead was successfully positioned in the right ventricle and
achieved pacing in 264 of 269 patients (98.1%). Two patients (0.8%) experienced loss
of pace capture. Procedural mean pace capture threshold (PCT) was 0.7 ± 0.8 mA.
There were no clinically significant perforations, pericardial effusions, or sustained
device-related arrhythmias. The Tempo lead was left in place postprocedure in
189 patients (71.6%) for mean duration of 43.3 ± 0.7 hr (range 2.5–221.3 hr) with
final PCT of 0.84 ± 1.04 mA (n = 80). Of these patients, 84.1% mobilized out of bed
with no lead dislodgment.
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Conclusion: The Tempo lead is safe and effective for temporary cardiac pacing for
structural heart procedures, provides stable peri and postprocedural pacing and
allows mobilization of patients who require temporary pacing leads.
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1 | INTRODUCTION
The use of temporary pacing has significantly increased as a necessary
adjunct to transcatheter aortic valve replacement (TAVR) and other
structural heart interventions. Many of these procedures require the
precise placement of implantable devices, which can be achieved by
rapid ventricular pacing with a temporary pacing lead.1 Furthermore,
approximately 5–30% of TAVR patients and 10–15% of alcohol septal
ablation (ASA) patients develop periprocedural cardiac conduction dis-
turbances requiring permanent pacemaker implantation.2–4 At-risk
patients, such as those with preexisting right bundle branch block or
new left bundle branch block after TAVR, may require retention of a
temporary pacing lead for several days as a precaution against the
development of complete heart block or other dangerous
bradyarrhythmias.
The standard design of temporary pacing leads consists of two rigid
metal electrodes mounted at and near the distal tip of an insulated
electrical wire. This design has been associated with cardiac perforation
and tamponade in up to 0.6–4.0% of cases5–9 and lead dislodgment
with loss of capture in 10–37% of patients.7,10,11 In addition, the stan-
dard lead design does not allow patient mobilization or ambulation,
which may affect patient comfort, delay mobilization, prolong intensive
care unit and hospital length of stay, and impact costs. The novel
Tempo® Temporary Pacing Lead (BioTrace Medical, Inc., Menlo Park,
CA) has a soft distal tip to reduce the risk of cardiac perforation and
allows active lead fixation to ensure reliable pace capture during the
index procedure and during subsequent patient mobilization.12
The aim of this study is to evaluate the safety and efficacy of the
Tempo lead for intra- and postprocedural cardiac pacing support in a




The Tempo lead (Figure 1) is a radiopaque, polymeric lead that fea-
tures bipolar electrodes, a novel active fixation mechanism designed
to enhance pacing stability, and a soft tip to minimize the risk of right
F IGURE 1 The Tempo Temporary Pacing Lead features bipolar
electrodes, active fixation to ensure stable pace capture, and a soft tip
to reduce the risk of right ventricle perforation [Color figure can be
viewed at wileyonlinelibrary.com]
F IGURE 2 The Tempo lead's active fixation is accomplished via
small retractable stabilizer loops deployed into the myocardium. An
elastomeric balloon inflates to aid passage through the venous
vasculature and into the right ventricle and provides apposition of the
stabilizer loops to the myocardium. The balloon is deflated after the
stabilizer loops are deployed [Color figure can be viewed at
wileyonlinelibrary.com]
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ventricular perforation. Active fixation is accomplished via small,
retractable nitinol stabilizer loops that are deployed into the myocar-
dium. An elastomeric balloon, mounted asymmetrically on the lead
body between the electrodes, aids passage through the venous vascu-
lature and provides apposition of the loops to the right ventricular
myocardium (Figure 2). The lead is readily visualized by fluoroscopy,
and an asymmetric orientation marker is used to orient the stabilizer
loops toward the ventricular septum (Figure 3). The Tempo lead has
been cleared by the U.S. Food and Drug Administration for temporary
transvenous cardiac pacing for up to 7 days.
2.2 | Study design and patient population
This is a retrospective, nonrandomized, multicenter registry study. Data
was collected from six high-volume, structural heart centers in the
United States for consecutive patients who underwent transcatheter
structural heart procedures using the Tempo lead. Subjects were
included if the Tempo lead entered the vascular introducer sheath.
Patient care was per institutional standard of care at the participating
centers during the period of study. The study was approved by the local
Institutional Review Board at each participating institution.
2.3 | Endpoints
The primary safety outcome consisted of device-related adverse events,
including clinically evident cardiac perforation, new pericardial effusion,
and sustained ventricular arrhythmia. The primary efficacy endpoint was
defined as successful lead placement with clinically acceptable pacing
capture threshold (PCT) and stable cardiac pacing during the index pro-
cedure. Procedural success was defined as the ability to advance the
Tempo lead to the right ventricle and to achieve right ventricular pacing.
Pace capture thresholds and stability during the implant period were
analyzed. Postprocedural practice patterns, including patient ambulation
and overall and intensive care unit length of stay, were also evaluated.
2.4 | Statistical analysis
Results are depicted as mean ± SD for numerical data and percentage
for categorical data. All comparisons are descriptive in nature.
3 | RESULTS
A total of 269 patients were included from six centers in the United
States. Baseline demographic, clinical, electrocardiographic, and echo-
cardiographic patient characteristics are presented in Table 1. The
mean age was 77.7 ± 10.4 years, and 64.3% of patients were male.
Patients had significant medical comorbidities, including coronary
artery disease (61.6%), chronic kidney disease (45.0%), and diabetes
mellitus (36.4%). Prior permanent pacemaker or automated implant-
able cardioverter defibrillators were present in 5.6% of the patients.
The mean left ventricular ejection fraction was 57.6 ± 12%, and
13.3% of the patients had moderate/severe tricuspid regurgitation.
3.1 | Procedural characteristics
Procedural characteristics and the distribution of the structural heart
procedures performed with the Tempo lead are presented in Table 2.
The procedures included 251 (93.3%) TAVRs (57.6% self-expanding
and 35.7% balloon-expandable transcatheter heart valve), 12 (4.5%)
ASA, and 6 (2.2%) other transcatheter structural heart interventions.
The Tempo lead was placed by jugular venous access in 58.7% of the
cases and femoral venous access in the remaining 41.3%.
3.2 | Outcomes
Procedural success was achieved in 98.1% (264/269) of cases and sta-
ble capture was achieved in all but two cases such that the primary effi-
cacy endpoint was met in 97.4% (262/269) of patients (Table 3). The
five unsuccessful lead placements included two from the right femoral
vein, two from the left femoral vein, and one from right internal jugular
vein. In the two patients (0.8%) with lead dislodgment and loss of pacing
capture (both inserted via the right internal jugular vein), repositioning
of the lead led to successful pacing. The immediate post implantation
PCT was collected in 92.4% (244/264) of patients in whom the Tempo
lead was successfully implanted and was 0.70 ± 0.77 mA. The primary
safety endpoint (absence of clinically significant cardiac perforation, new
pericardial effusion, and sustained ventricular arrhythmia) was met in all
patients. Lead removal was free of complications in all patients.
F IGURE 3 (a) Fluoroscopic view of the Tempo lead in the right
ventricular apex. (b) Fluoroscopic view of the Tempo lead
demonstrating the soft tip in the right ventricular apex, the
orientation marker, and the deployed active fixation stabilizer loops
[Color figure can be viewed at wileyonlinelibrary.com]
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The Tempo lead was left in place in 71.6% (189/264) of patients at
the end of the index procedure (Table 4). The mean total pacing duration
was recorded in 87.8% (166/189) of these patients and was 43.3 ± 0.7 hr
(range 2.5–221.3 hr). With the Tempo lead in place, 159/189 patients
(84.1%) mobilized at least from bed to chair, and 134/189 (70.8%) ambu-
lated without restriction related to the pacing lead. There were no reports
of lead dislodgment or loss of pace capture. The final PCT before lead
removal was reported in 39.2% (74/189) and was 0.82 ± 1.07 mA.
4 | DISCUSSION
This study evaluated the safety and efficacy of the Tempo temporary
pacing lead in a large real-world registry of patients undergoing trans-
catheter heart interventions at six high-volume centers in the United
States. In this experience, the Tempo lead provided effective temporary
cardiac pacing during the procedure in more than 97% of patients.
PCTs were within a clinically acceptable range and pacing remained sta-
ble throughout the procedure in the vast majority. The Tempo lead was
retained in situ after the procedure in more than 70% of patients and
continued to function well during patient mobilization and ambulation.
The primary safety endpoint was met in all patients, with no reported
device-related adverse events, including clinically evident cardiac perfo-
ration, new pericardial effusion, or sustained ventricular arrhythmia.
Temporary pacing leads serve important intra and postprocedural
roles in structural heart procedures. During transcatheter valve replace-
ment procedures, temporary pacing is frequently used for TAVR device
stability during deployment, and rapid pacing is mandatory in the case of
balloon-expandable TAVR and transcatheter mitral valve replace-
ment.13,14 Lead dislodgment or loss of pace capture in this setting can
TABLE 2 Procedural characteristics
Structural heart procedure
TAVR with self-expanding valve 57.6% (155/269)
TAVR with balloon-expandable valve 35.7% (96/269)
Alcohol septal ablation 4.5% (12/269)
Other 2.2% (6/269)
Access for Tempo lead placement
Femoral vein 41.3% (111/269)
Internal jugular vein 58.7% (158/269)
Note: Values are % (n/N).
Abbreviation: TAVR, transcatheter aortic valve replacement.
TABLE 3 Lead safety and performance during index procedure
Procedural success (successful lead
placement with right ventricular pacing)
98.1% (264/269)
Primary efficacy endpoint (procedural
success and stable pacing during index
procedure)
97.4% (262/269)
Primary safety endpoint (device-related adverse
events)
0.0% (0/269)
Cardiac perforation and/or tamponade 0.0% (0/269)
Sustained arrhythmias 0.0% (0/269)
Immediate post implantation, procedural pace
capture threshold
0.70 ± 0.77 mA
(244)
Note: Values are % (n/N) or mean ± SD (n).
TABLE 4 Postprocedure lead use
Patients in whom Tempo lead was
left in place at the end of the procedure
71.6% (189/264)
Lead dislodgment 0.0% (0/189)
Cardiac perforation and/or tamponade 0.0% (0/189)
Sustained arrhythmias 0.0% (0/189)
Mean implant duration (hours) 43.3 ± 0.7 (136)
Final pace capture threshold 0.84 ± 1.04 mA
(80)
Mobility
Bed to chair 84.1% (159/189)
Ambulation 70.8% (134/189)
Mean implant duration (hours) 44.5 ± 0.5 (140)
Final (before the removal of the lead)
postprocedural pace capture threshold
0.82 ± 1.07 mA
(74)
Note: Values are % (n/N) or mean ± SD (n).
TABLE 1 Baseline patient characteristics
Age 77.7 ± 10.4
years (269)
Male sex 64.3% (173/269)
History of smoking 28.6% (77/269)
Hypertension 85.5% (230/269)
Diabetes mellitus 36.4% (98/269)
Coronary artery disease 60.6% (163/269)
Prior PPM or AICD 5.6% (15/269)
Chronic kidney disease 45.0% (121/269)
Pulmonary hypertension 22.3% (60/269)
COPD 20.8% (56/269)
Baseline echocardiogram
LV ejection fraction (%) 57.6 ± 12.1 (267)
RV dilation (moderate to severe) 7.4% (19/256)
Tricuspid regurgitation (moderate to severe) 13.3% (34/256)
Baseline electrocardiogram
Atrial fibrillation/flutter 21.9% (59/269)
Sinus bradycardia 12.2% (28/229)
First degree AVB 21.2% (57/269)
Second degree AVB 0.4% (1/269)
RBBB (complete) 13.4% (35/261)
LBBB (complete) 7.3% (19/261)
Note: Values are % (n/N) or mean ± SD (n).
Abbreviations: AICD, automatic implantable cardioverter-defibrillator;
AVB, atrioventricular block; COPD, chronic obstructive pulmonary
disease; LBBB, left bundle branch block; LV, left ventricular; PPM,
permanent pacemaker RBBB, right bundle branch block; RV, right
ventricular.
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result in valve embolization.15,16 Pacing support is also necessary in case
of heart block and related conduction disturbances, which can occur dur-
ing or after transcatheter heart valve implantation or ASA in patients with
hypertrophic cardiomyopathy.2,4 Since conduction disturbances may be
delayed in onset, pacing leads are frequently left in situ after the index
procedure and may limit patient mobilization.17,18 This practice may also
prolong length of stay especially in intensive or cardiac care unit settings.
Structural heart interventions have traditionally relied on the use
of conventional temporary transvenous bipolar cardiac pacing leads
consisting of two rigid metal electrodes mounted at and approxi-
mately 1 cm from the distal tip of an insulated electrical wire. This
technology has not improved significantly in decades and is associated
with important limitations, including instability and a risk of cardiac
perforation. Because standard temporary pacing leads do not include
an active myocardial fixation mechanism, they have traditionally been
associated with high rates of lead dislodgment and loss of pace
capture.6,7,9–11,19 The use of these leads during TAVR has also been
associated with cardiac perforation and tamponade, ranging from 0.6
to 4.0% in different series, presumably due to the stiff distal tip of
these leads.20–24 Although temporary pacing leads with a distal screw
for active myocardial fixation have been used to attempt to reduce
dislodgment and loss of pace capture, these leads have exhibited dis-
lodgment rates of up to 6%. Furthermore, distal screw fixation tem-
poraory leads have been associated with cardiac perforation rates as
high as 23% and are no longer available.25,26 Some centers have also
used a permanent pacing lead that is externalized through the vascular
introducer sheath and connected to an external permanent pace-
maker.27 However, this approach, is technically more complex, pre-
sents perforation risk, and may not be cost effective.
The Tempo lead was designed to address the limitations of conven-
tional temporary leads. The soft distal tip is designed to be atraumatic
during placement and retention in the right ventricle and is radiopaque
to allow ready visualization under fluoroscopy. Two small Nitinol stabi-
lizer loops allow for active lead fixation to ensure stable pace capture,
while mitigating the risk of perforation due to their small diameter and
asymmetric orientation with preferential deployment into the thicker
interventricular septum. These stabilizers are readily deployed and ret-
racted using a spring-loaded external handle-delivery system at the
proximal end of the lead. (Figure 2). An asymmetric, elastomeric balloon
assists in transit through the venous access and serves to oppose the
lead to the interventricular septal wall during stabilizer deployment.
The lead is indicated for use for up to 7 days and, given the novel active
fixation mechanism, allows for early patient mobilization.
The current analysis reinforces the results of the previously
described first in human experience in New Zealand using the Tempo
lead in 25 patients undergoing transcatheter structural heart interven-
tions and electrophysiology procedures.12 As in the current study, the
implantation of the Tempo temporary pacing lead was technically fea-
sible and safe for intraprocedural and postprocedural pacing support.
In the current, substantially larger registry of 269 patients, the rates of
procedural success and safety endpoints remain similar, expanding the
existing safety and efficacy data regarding Tempo lead utilization dur-
ing various structural heart interventions.
Among patients in this analysis in whom the Tempo lead was left in
place after the procedure, more than 80% were mobilized out of bed
with maintenance of clinically acceptable PCTs and no reported loss of
pacing capture. This is in contrast to the previously existing standard of
care at the institutions included in this analysis of mandatory bed rest
for patients who required temporary pacing leads. Early mobilization in
critically ill patients has been shown to be associated with decreased
rates of delirium, readmission or death, ventilator-assisted pneumonia,
and central line and catheter infections.28 The Tempo lead's active fixa-
tion mechanism may also allow some patients with postprocedure con-
duction disturbances to recover on general hospital wards rather than
in the intensive care unit with reduced in-hospital costs. This may also
allow for a greater window of time before the decision to implant a per-
manent pacemaker is required in patients with conduction disturbances
that may ultimately resolve in a substantial proportion of cases.
5 | STUDY LIMITATIONS
The present study has several limitations. Although it is a relatively
large, multicenter registry study, the use of site-reported data and the
retrospective nature of the analysis are subject to the inherent limita-
tions of this methodology. Diagnostic tests, including electrocardio-
grams and echocardiograms, were performed and interpreted only
according to local institutional standards of care. As the current study
did not include a control group (patients treated with a classic tempo-
rary transvenous pacemaker lead), direct comparisons regarding safety,
efficacy, and postprocedure mobilization are also not possible. Although
there were no reports of lead dislodgment or loss of pace capture dur-
ing patient mobilization, the final PCT before lead removal was
reported only in 39.2% and thus this data may be biased. Finally, struc-
tural heart procedures other than TAVR are underrepresented and the
generalizability of the results beyond this group of patients is unknown.
6 | CONCLUSION
This multi-center, retrospective analysis of the initial real-world expe-
rience in the United States demonstrates that the Tempo lead is tech-
nically feasible, safe, and effective for temporary cardiac pacing for
transcatheter structural heart interventions. The Tempo lead provides
stable peri and postprocedural pacing support and allows mobilization
of patients who require temporary pacing leads.
DISCLOSURE OF INTERESTS
BioTrace Medical provided funding for this research. Tamim Nazif and
Susheel Kodali disclose consulting for BioTrace Medical. Tamim Nazif,
Susheel Kodali, and John Forest disclose consulting or honoraria for
Edwards LifeSciences, Medtronic, and Boston Scientific. Brian Whisenant
discloses equity in BioTrace Medical. Carlos Sanchez discloses consulting
for Edwards LifeSciences and Medtronic. Paul Michael Grossman dis-
closes consulting for Medtronic Cardiovascular, research support from
Medtronic Cardiovascular, Edwards Life Sciences, and Cardiovascular
NAZIF ET AL. 1055
Systems Incorporated, registry support from Blue Cross Blue Shield of
Michigan, and research support from National Institutes of Health.
ORCID
Tamim M. Nazif https://orcid.org/0000-0003-1239-2489
Shmuel Chen https://orcid.org/0000-0001-8843-1777
Carlos E. Sanchez https://orcid.org/0000-0002-1818-4472




1. Webb JG, Pasupati S, Achtem L, Thompson CR. Rapid pacing to facili-
tate transcatheter prosthetic heart valve implantation. Catheter
Cardiovasc Interv. 2006;68:199-204.
2. Auffret V, Puri R, Urena M, et al. Conduction disturbances after trans-
catheter aortic valve replacement: current status and future perspec-
tives. Circulation. 2017;136:1049-1069.
3. Siontis GC, Juni P, Pilgrim T, et al. Predictors of permanent pacemaker
implantation in patients with severe aortic stenosis undergoing TAVR.
A Meta-Anal J Am Coll Cardiol. 2014;64:129-140.
4. Fitzgerald P, Kusumoto F. The effects of septal myectomy and alcohol
septal ablation for hypertrophic cardiomyopathy on the cardiac con-
duction system. J Interv Card Electrophysiol. 2018;52:403-408.
5. Metkus TS, Schulman SP, Marine JE, Eid SM. Complications and out-
comes of temporary transvenous pacing: an analysis of >360,000
patients from the National Inpatient Sample. Chest. 2019;155:
749-757.
6. Lopez Ayerbe J, Villuendas Sabate R, Garcia Garcia C, et al. Tempo-
rary pacemakers: current use and complications. Rev Esp Cardiol.
2004;57:1045-1052.
7. Betts TR. Regional survey of temporary transvenous pacing proce-
dures and complications. Postgrad Med J. 2003;79:463-465.
8. Jowett NI, Thompson DR, Pohl JE. Temporary transvenous cardiac
pacing: 6 years experience in one coronary care unit. Postgrad Med J.
1989;65:211-215.
9. Austin JL, Preis LK, Crampton RS, Beller GA, Martin RP. Analysis of
pacemaker malfunction and complications of temporary pacing in the
coronary care unit. Am J Cardiol. 1982;49:301-306.
10. Gammage MD. Temporary cardiac pacing. Heart. 2000;83:715-720.
11. Lumia FJ, Rios JC. Temporary transvenous pacemaker therapy: an
analysis of complications. Chest. 1973;64:604-608.
12. Webster M, Pasupati S, Lever N, Stiles M. Safety and feasibility of a
novel active fixation temporary pacing Lead. J Invasive Cardiol. 2018;
30:163-167.
13. Mauri V, Reimann A, Stern D, et al. Predictors of permanent pace-
maker implantation after transcatheter aortic valve replacement with
the SAPIEN 3. JACC Cardiovasc Interv. 2016;9:2200-2209.
14. Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors,
and outcomes of permanent pacemaker implantation following trans-
catheter aortic valve replacement: Analysis from the U.S. Society of
Thoracic Surgeons/American College of Cardiology TVT Registry.
JACC Cardiovasc Interv. 2016;9:2189-2199.
15. Ibebuogu UN, Giri S, Bolorunduro O, et al. Review of reported causes
of device embolization following trans-catheter aortic valve implanta-
tion. Am J Cardiol. 2015;115:1767-1772.
16. Tay EL, Gurvitch R, Wijeysinghe N, et al. Outcome of patients after
transcatheter aortic valve embolization. JACC Cardiovasc Interv.
2011;4:228-234.
17. Mangieri A, Lanzillo G, Bertoldi L, et al. Predictors of advanced con-
duction disturbances requiring a late (>/=48 H) permanent pacemaker
following transcatheter aortic valve replacement. JACC Cardiovasc
Interv. 2018;11:1519-1526.
18. Jorgensen TH, De Backer O, Gerds TA, Bieliauskas G, Svendsen JH,
Sondergaard L. Immediate post-procedural 12-Lead electrocardiogra-
phy as predictor of late conduction defects after transcatheter aortic
valve replacement. JACC Cardiovasc Interv. 2018;11:1509-1518.
19. Murphy JJ. Current practice and complications of temporary trans-
venous cardiac pacing. BMJ. 1996;312:1134.
20. Bosmans JM, Kefer J, De Bruyne B, et al. Procedural, 30-day and one
year outcome following CoreValve or Edwards transcatheter aortic
valve implantation: results of the Belgian national registry. Interact
Cardiovasc Thorac Surg. 2011;12:762-767.
21. Grube E, Buellesfeld L, Mueller R, et al. Progress and current status of
percutaneous aortic valve replacement: results of three device gener-
ations of the CoreValve Revalving system. Circ Cardiovasc Interv.
2008;1:167-175.
22. Piazza N, Onuma Y, Jesserun E, et al. Early and persistent intraven-
tricular conduction abnormalities and requirements for pacemaking
after percutaneous replacement of the aortic valve. JACC Cardiovasc
Interv. 2008;1:310-316.
23. El Masry H, Breall JA. Alcohol septal ablation for hypertrophic obstruc-
tive cardiomyopathy. Curr Cardiol Rev 2008;4:193–197.
24. Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic
stenosis with the percutaneous heart valve: mid-term follow-up from
the initial feasibility studies: the French experience. J Am Coll Cardiol.
2006;47:1214-1223.
25. de Cock CC, Van Campen CM, In't Veld JA, Visser CA. Utility and
safety of prolonged temporary transvenous pacing using an active-
fixation lead: comparison with a conventional lead. Pacing Clin Elec-
trophysiol. 2003;26:1245-1248.
26. Chauhan A, Grace AA, Newell SA, et al. Early complications after dual
chamber versus single chamber pacemaker implantation. Pacing Clin
Electrophysiol. 1994;17:2012-2015.
27. Leong D, Sovari AA, Ehdaie A, et al. Permanent-temporary pace-
makers in the management of patients with conduction abnormalities
after transcatheter aortic valve replacement. J Interv Card Electro-
physiol. 2018;52:111-116.
28. Hunter A, Johnson L, Coustasse A. Reduction of intensive care unit
length of stay: the case of early mobilization. Health Care Manag
(Frederick). 2014;33:128-135.
How to cite this article: Nazif TM, Chen S, Codner P, et al.
The initial U.S. experience with the Tempo active fixation
temporary pacing lead in structural heart interventions.
Catheter Cardiovasc Interv. 2020;95:1051–1056. https://doi.
org/10.1002/ccd.28476
1056 NAZIF ET AL.
